Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
213 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Metastatic Renal Cell Carcinoma - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Metastatic Renal Cell Carcinoma - Pipeline Review, H1 2015', provides an overview of the Metastatic Renal Cell Carcinoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Renal Cell Carcinoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Renal Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Renal Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Renal Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Renal Cell Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Metastatic Renal Cell Carcinoma Overview 8 Therapeutics Development 9 Pipeline Products for Metastatic Renal Cell Carcinoma - Overview 9 Pipeline Products for Metastatic Renal Cell Carcinoma - Comparative Analysis 10 Metastatic Renal Cell Carcinoma - Therapeutics under Development by Companies 11 Metastatic Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 15 Metastatic Renal Cell Carcinoma - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Metastatic Renal Cell Carcinoma - Products under Development by Companies 20 Metastatic Renal Cell Carcinoma - Products under Investigation by Universities/Institutes 23 Metastatic Renal Cell Carcinoma - Companies Involved in Therapeutics Development 24 Acceleron Pharma, Inc. 24 Activartis Biotech GmbH 25 AlphaMab Co., Ltd 26 Amgen Inc. 27 Angiogene Pharmaceuticals Ltd. 28 Argos Therapeutics, Inc. 29 Astellas Pharma Inc. 30 Beta Pharma, Inc. 31 Bionomics Limited 32 Cerulean Pharma, Inc. 33 Conkwest, Inc. 34 Debiopharm International S.A. 35 Eisai Co., Ltd. 36 Eli Lilly and Company 37 Epirus Biopharmaceuticals, Inc. 38 Exelixis, Inc. 39 Genor BioPharma Co., Ltd. 40 Hospira, Inc. 41 immatics biotechnologies GmbH 42 Immune Design Corp. 43 Immunicum AB 44 Inbiopro Solutions Pvt. Ltd. 45 Jiangsu Hengrui Medicine Co., Ltd. 46 Mabion SA 47 NewLink Genetics Corporation 48 Novartis AG 49 Ono Pharmaceutical Co., Ltd. 50 Panacea Biotec Limited 51 Peloton Therapeutics, Inc. 52 Prima BioMed Ltd. 53 Rexahn Pharmaceuticals, Inc. 54 Seattle Genetics, Inc. 55 Syndax Pharmaceuticals, Inc. 56 TVAX Biomedical, Inc. 57 Metastatic Renal Cell Carcinoma - Therapeutics Assessment 58 Assessment by Monotherapy Products 58 Assessment by Target 59 Assessment by Mechanism of Action 62 Assessment by Route of Administration 65 Assessment by Molecule Type 67 Drug Profiles 69 AGS-003 - Drug Profile 69 AGS-16C3F - Drug Profile 72 AGS-16M8F - Drug Profile 73 aldesleukin - Drug Profile 74 AV0-113 - Drug Profile 75 bevacizumab biosimilar - Drug Profile 76 bevacizumab biosimilar - Drug Profile 77 bevacizumab biosimilar - Drug Profile 78 bevacizumab biosimilar - Drug Profile 79 bevacizumab biosimilar - Drug Profile 80 bevacizumab biosimilar - Drug Profile 81 bevacizumab biosimilar - Drug Profile 82 bevacizumab biosimilar - Drug Profile 83 BNC-105 - Drug Profile 84 BNC-105P - Drug Profile 85 BPI-3119 - Drug Profile 87 cabozantinib s-malate - Drug Profile 88 CRLX-101 - Drug Profile 91 CST-101 - Drug Profile 93 dalantercept - Drug Profile 95 Debio-0932 - Drug Profile 97 Dendritic Cell Therapy for Metastatic Renal Cell Carcinoma and Melanoma - Drug Profile 99 entinostat - Drug Profile 100 everolimus - Drug Profile 104 G-305 - Drug Profile 109 Hyperacute For Renal Cancer - Drug Profile 110 IBPM-002BZ - Drug Profile 111 IMA-901 - Drug Profile 112 IMP-321 - Drug Profile 114 Intuvax - Drug Profile 116 lenvatinib - Drug Profile 117 LY-2510924 - Drug Profile 121 Monoclonal Antibody Conjugated to Target Cells Expressing Antigen G250 for Renal Cell Carcinoma - Drug Profile 122 nivolumab (recombinant) - Drug Profile 123 Orellanine - Drug Profile 128 panobinostat - Drug Profile 129 PT-2385 - Drug Profile 135 Recombinant Protein for Oncology - Drug Profile 136 rilotumumab - Drug Profile 137 RX-0201 - Drug Profile 139 SGN-CD70A - Drug Profile 141 SHR-1020 - Drug Profile 142 trebananib - Drug Profile 144 TVI-Kidney-1 - Drug Profile 147 ZD-6126 - Drug Profile 148 Metastatic Renal Cell Carcinoma - Recent Pipeline Updates 149 Metastatic Renal Cell Carcinoma - Dormant Projects 195 Metastatic Renal Cell Carcinoma - Discontinued Products 199 Metastatic Renal Cell Carcinoma - Product Development Milestones 200 Featured News & Press Releases 200 Appendix 209 Methodology 209 Coverage 209 Secondary Research 209 Primary Research 209 Expert Panel Validation 209 Contact Us 210 Disclaimer 210
List of Tables Number of Products under Development for Metastatic Renal Cell Carcinoma, H1 2015 12 Number of Products under Development for Metastatic Renal Cell Carcinoma - Comparative Analysis, H1 2015 13 Number of Products under Development by Companies, H1 2015 15 Number of Products under Development by Companies, H1 2015 (Contd..1) 16 Number of Products under Development by Companies, H1 2015 (Contd..2) 17 Number of Products under Investigation by Universities/Institutes, H1 2015 18 Comparative Analysis by Late Stage Development, H1 2015 19 Comparative Analysis by Clinical Stage Development, H1 2015 20 Comparative Analysis by Early Stage Development, H1 2015 21 Comparative Analysis by Unknown Stage Development, H1 2015 22 Products under Development by Companies, H1 2015 23 Products under Development by Companies, H1 2015 (Contd..1) 24 Products under Development by Companies, H1 2015 (Contd..2) 25 Products under Investigation by Universities/Institutes, H1 2015 26 Metastatic Renal Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H1 2015 27 Metastatic Renal Cell Carcinoma - Pipeline by Activartis Biotech GmbH, H1 2015 28 Metastatic Renal Cell Carcinoma - Pipeline by AlphaMab Co., Ltd, H1 2015 29 Metastatic Renal Cell Carcinoma - Pipeline by Amgen Inc., H1 2015 30 Metastatic Renal Cell Carcinoma - Pipeline by Angiogene Pharmaceuticals Ltd., H1 2015 31 Metastatic Renal Cell Carcinoma - Pipeline by Argos Therapeutics, Inc., H1 2015 32 Metastatic Renal Cell Carcinoma - Pipeline by Astellas Pharma Inc., H1 2015 33 Metastatic Renal Cell Carcinoma - Pipeline by Beta Pharma, Inc., H1 2015 34 Metastatic Renal Cell Carcinoma - Pipeline by Bionomics Limited, H1 2015 35 Metastatic Renal Cell Carcinoma - Pipeline by Cerulean Pharma, Inc., H1 2015 36 Metastatic Renal Cell Carcinoma - Pipeline by Conkwest, Inc., H1 2015 37 Metastatic Renal Cell Carcinoma - Pipeline by Debiopharm International S.A., H1 2015 38 Metastatic Renal Cell Carcinoma - Pipeline by Eisai Co., Ltd., H1 2015 39 Metastatic Renal Cell Carcinoma - Pipeline by Eli Lilly and Company, H1 2015 40 Metastatic Renal Cell Carcinoma - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 41 Metastatic Renal Cell Carcinoma - Pipeline by Exelixis, Inc., H1 2015 42 Metastatic Renal Cell Carcinoma - Pipeline by Genor BioPharma Co., Ltd., H1 2015 43 Metastatic Renal Cell Carcinoma - Pipeline by Hospira, Inc., H1 2015 44 Metastatic Renal Cell Carcinoma - Pipeline by immatics biotechnologies GmbH, H1 2015 45 Metastatic Renal Cell Carcinoma - Pipeline by Immune Design Corp., H1 2015 46 Metastatic Renal Cell Carcinoma - Pipeline by Immunicum AB, H1 2015 47 Metastatic Renal Cell Carcinoma - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 48 Metastatic Renal Cell Carcinoma - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 49 Metastatic Renal Cell Carcinoma - Pipeline by Mabion SA, H1 2015 50 Metastatic Renal Cell Carcinoma - Pipeline by NewLink Genetics Corporation, H1 2015 51 Metastatic Renal Cell Carcinoma - Pipeline by Novartis AG, H1 2015 52 Metastatic Renal Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 53 Metastatic Renal Cell Carcinoma - Pipeline by Panacea Biotec Limited, H1 2015 54 Metastatic Renal Cell Carcinoma - Pipeline by Peloton Therapeutics, Inc., H1 2015 55 Metastatic Renal Cell Carcinoma - Pipeline by Prima BioMed Ltd., H1 2015 56 Metastatic Renal Cell Carcinoma - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015 57 Metastatic Renal Cell Carcinoma - Pipeline by Seattle Genetics, Inc., H1 2015 58 Metastatic Renal Cell Carcinoma - Pipeline by Syndax Pharmaceuticals, Inc., H1 2015 59 Metastatic Renal Cell Carcinoma - Pipeline by TVAX Biomedical, Inc., H1 2015 60 Assessment by Monotherapy Products, H1 2015 61 Number of Products by Stage and Target, H1 2015 63 Number of Products by Stage and Mechanism of Action, H1 2015 66 Number of Products by Stage and Route of Administration, H1 2015 69 Number of Products by Stage and Molecule Type, H1 2015 71 Metastatic Renal Cell Carcinoma Therapeutics - Recent Pipeline Updates, H1 2015 152 Metastatic Renal Cell Carcinoma - Dormant Projects, H1 2015 198 Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..1), H1 2015 199 Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..2), H1 2015 200 Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..3), H1 2015 201 Metastatic Renal Cell Carcinoma - Discontinued Products, H1 2015 202
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.